The document discusses career options for life scientists with PhDs. It begins with a brief history of biotechnology, noting 1980 as a seminal year when the Bayh-Dole Act and a Supreme Court ruling enabled university patenting and commercialization of research. This shifted the focus from solely publishing to also patenting and technology transfer. The document outlines traditional career paths for PhDs but notes a disconnect between university education and non-academic options. It encourages cross-disciplinary training and developing unique qualifications to work at the interfaces of science, business, law, and technology.
This document summarizes the role and activities of Stanford University's Office of Technology Licensing (OTL). The OTL is responsible for evaluating inventions created by Stanford researchers, obtaining intellectual property protection, marketing inventions to potential licensees, and negotiating licenses that generate income for the university while allowing companies to commercialize technologies. It discusses OTL's process for working with researchers and startups. The OTL aims to transfer Stanford technologies to benefit society and support further research.
Connecting education tech society laura erickson3helix
The document discusses connecting education, innovation, and society through initiatives like swissnex, which is a worldwide network of knowledge outposts established by the State Secretariat for Education and Research of Switzerland. It highlights the importance of knowledge and education as currency for fueling entrepreneurship and innovation through collaboration between universities, research institutions, talent, venture capital firms, and companies in areas like the San Francisco Bay Area.
This document provides information about a career fair for Ph.D. and Master's students being held on November 17, 2011 in Chapel Hill, NC. It lists 17 organizations that will be present at the fair, along with a brief overview of each organization, their website, the areas of study they are seeking to recruit for, and whether they are open to Master's students, Ph.D. candidates, those with a Ph.D. degree, or international candidates. The organizations span various fields including engineering, computer science, healthcare, social sciences, and more.
Battery Management System For Electric Vehicle Applications.pdfInstansi
This thesis discusses battery management systems (BMS) for electric vehicle applications. It presents an improved battery model that accounts for self-discharging, temperature effects, and capacity fading. Simulation results show the model can accurately simulate charging, discharging, and cell balancing processes. The thesis also details a BMS hardware system designed using Texas Instruments components. It was improved with a user interface, thermal management, and current monitoring. Experimental results validated the BMS system's performance in monitoring and protecting lithium-ion battery packs.
Shaik Mohamed Salih SMA is seeking an entry-level position in engineering. He has a Master's degree in Control and Instrumentation from St. Xavier's College of Engineering and a Bachelor's degree in Electronics and Communication from A.M.S. College of Engineering. He has work experience as an industrial trainee in instrumentation and training in industrial automation. His skills include DCS, PLC, MATLAB, LabVIEW, and he is interested in control systems, measurements and instrumentation, and mobile communication.
This document is a resume for Danna P. Iñigo, who is currently studying Associate in Information Technology at Laguna State Polytechnic University. Her objectives include applying what she learns in her course, gaining work experience, and being open to new ideas. Additional details provided include her personal profile, educational background, training and seminars attended, skills, and character references.
The document discusses science entrepreneurship and examples of scientists who have become wealthy entrepreneurs. It provides several case studies of scientists who started successful companies in fields like pharmaceuticals, biotechnology, computers, and telecommunications. It discusses how universities are becoming more entrepreneurial and how this is allowing some scientists to earn substantial fortunes by commercializing their research through new companies.
This document summarizes the role and activities of Stanford University's Office of Technology Licensing (OTL). The OTL is responsible for evaluating inventions created by Stanford researchers, obtaining intellectual property protection, marketing inventions to potential licensees, and negotiating licenses that generate income for the university while allowing companies to commercialize technologies. It discusses OTL's process for working with researchers and startups. The OTL aims to transfer Stanford technologies to benefit society and support further research.
Connecting education tech society laura erickson3helix
The document discusses connecting education, innovation, and society through initiatives like swissnex, which is a worldwide network of knowledge outposts established by the State Secretariat for Education and Research of Switzerland. It highlights the importance of knowledge and education as currency for fueling entrepreneurship and innovation through collaboration between universities, research institutions, talent, venture capital firms, and companies in areas like the San Francisco Bay Area.
This document provides information about a career fair for Ph.D. and Master's students being held on November 17, 2011 in Chapel Hill, NC. It lists 17 organizations that will be present at the fair, along with a brief overview of each organization, their website, the areas of study they are seeking to recruit for, and whether they are open to Master's students, Ph.D. candidates, those with a Ph.D. degree, or international candidates. The organizations span various fields including engineering, computer science, healthcare, social sciences, and more.
Battery Management System For Electric Vehicle Applications.pdfInstansi
This thesis discusses battery management systems (BMS) for electric vehicle applications. It presents an improved battery model that accounts for self-discharging, temperature effects, and capacity fading. Simulation results show the model can accurately simulate charging, discharging, and cell balancing processes. The thesis also details a BMS hardware system designed using Texas Instruments components. It was improved with a user interface, thermal management, and current monitoring. Experimental results validated the BMS system's performance in monitoring and protecting lithium-ion battery packs.
Shaik Mohamed Salih SMA is seeking an entry-level position in engineering. He has a Master's degree in Control and Instrumentation from St. Xavier's College of Engineering and a Bachelor's degree in Electronics and Communication from A.M.S. College of Engineering. He has work experience as an industrial trainee in instrumentation and training in industrial automation. His skills include DCS, PLC, MATLAB, LabVIEW, and he is interested in control systems, measurements and instrumentation, and mobile communication.
This document is a resume for Danna P. Iñigo, who is currently studying Associate in Information Technology at Laguna State Polytechnic University. Her objectives include applying what she learns in her course, gaining work experience, and being open to new ideas. Additional details provided include her personal profile, educational background, training and seminars attended, skills, and character references.
The document discusses science entrepreneurship and examples of scientists who have become wealthy entrepreneurs. It provides several case studies of scientists who started successful companies in fields like pharmaceuticals, biotechnology, computers, and telecommunications. It discusses how universities are becoming more entrepreneurial and how this is allowing some scientists to earn substantial fortunes by commercializing their research through new companies.
This document discusses strategies for addressing unmet medical needs through university intellectual property and licensing. It provides examples of the University of California, Berkeley's Socially Responsible Licensing Program, which includes contract clauses focused on access and affordability for neglected diseases and populations. The document outlines challenges in balancing commercial incentives with social welfare needs. It proposes combining contract terms, intellectual property strategies, and business models in different permutations to create incentives for developing products addressing unmet needs. Partnerships between universities, companies, and non-profits are presented as ways to accelerate innovation and de-risk product development for neglected areas.
The document discusses Mass CONNECT, a program that aims to leverage industry networks to advance translational research and bridge the "translation gap" between academic discoveries and early-stage commercial opportunities. The program provides mentoring, industry screening of technologies, and connections to proven industry advisors and networks to accelerate promising opportunities and increase the throughput of technologies out of academic offices. It describes the ideal profiles of technologies and investigators that would benefit from the program.
This document discusses the importance of collaborations between universities and industry, especially for natural product research. It notes that universities have become the primary source of biopharma innovation and discovery. However, natural product research presents challenges such as long timelines, complex sourcing and production, and uncertain patent and regulatory frameworks. The document emphasizes that university collaborations are critical for the biopharma industry to overcome these challenges. It also discusses the role of intellectual property in facilitating innovation through licensing between academia and industry.
Life Science Alternative Careers WorkshopMary Canady
This document summarizes a panel discussion on alternative careers for scientists. The panelists discussed their paths to careers in science writing, regulatory affairs, business development, and science policy. For science writing, the panelist recommended building a portfolio by volunteering to write and establishing goals. For regulatory affairs, the panelist discussed their transition from discovery research and strategies for gaining entry-level experience. Other panelists provided overviews of their careers in business development and policy fellowships. The discussion offered advice on networking, gaining relevant experience, and specializing to explore alternative career options outside of research.
The document discusses career opportunities in intellectual property for biomedical engineers, including working in patent law. It outlines that industry careers in areas like medical devices, diagnostics, and therapeutics involve intellectual property. For those interested in intellectual property specifically, skills in literature searching, patent searching, technical writing and understanding the medical industry are important. The document provides an example of analyzing disclosed inventions for commercialization potential as part of a job at an Office of Technology Management.
The document discusses the role of the UAB Research Foundation in technology transfer and commercializing intellectual property created at UAB. It notes that the RF handles around 1,000 agreements annually and owns the intellectual property from UAB's over $420 million in annual research expenditures. The RF aims to license patents and support Alabama's entrepreneurial ecosystem through collaborations within UAB and the local community that can help discoveries become commercial products and services.
What to know if it is your first rodeo in patent monetization.pptxturo6
What is patent monetization and how does it differ from a typical licensing deal?
The process of due diligence for patent monetization - how do you choose patents which would be great candidates for monetization?
What are some of the intangibles at institutions that prevent patent monetization?
How do you convince your institution about patent monetization?
The business model for patent monetization? Who pays for it? What's in it for me? What do net revenues vs gross revenue really mean in the context of monetization?
Legal considerations for patent monetization. What are some of the risks?
How long does it take? How do the recent policy changes and case law impact patent monetization?
Is patent monetization ethical?
These and many more topics will be covered in great detail with an opportunity to ask questions to the panelists who are world-leading experts in business, legal, and policy matters.
PLx Pharma is developing next generation NSAIDs to improve gastrointestinal (GI) safety. Jason Moore, Vice President of PLx Pharma, gave a presentation about positioning oneself for a leadership career in biotech and about the challenges faced by PLx Pharma, including developing drugs with improved GI safety profiles to address the large market for osteoarthritis pain relief while managing various risks in the drug development process such as technical, regulatory, financial and commercial risks.
The document discusses a manufacturing platform for producing therapeutics in tobacco plants. It summarizes meetings with experts on commercializing biotech platforms and understanding customers. Experts advised validating the platform by producing hard-to-make proteins, focusing on technical/manufacturing customers, and understanding regulatory issues. Customers cited interest in cost-effective production and combination vaccines. Next steps include further challenging the value proposition and better understanding commercialization and decision-making processes through additional expert meetings.
The document discusses best practices for technology transfer offices (TTOs) based on a conference presentation. It covers why technology transfer is important, key laws enabling tech transfer in the US, examples of university tech transfer success, and lessons learned regarding evaluating intellectual property, patenting, licensing, and starting new companies.
Presented by Dr. Tom Corr, CEO – Waterloo Research and Technology Park Accelerator Centre & Associate Vice President, Commercialization – University of Waterloo
Part of the Ontario Post Doctoral Fellowship Networking Event, October 6, 2008
TOPICS
Research Funding
Who Owns the Intellectual Property?
Commercialization Options
Dealing with VCs
Outcomes of Commercialization Efforts
Innovative and New Programs in Biotechnology and Biomanufacturing bio-link
This year’s panel features programs noteworthy in their approach to biotechnology/biomanufacturing education and training and the workforce. Panelists include leaders of the Lone Star Biotechnology Institute at Lone Star College working with the local biomedical and biofuels industry in Houston, TX; the Biomass Production Training Certificate at Mira Costa College part of the EDGE (Educating and Developing Workers for the Green Economy) initiative for San Diego County, CA; the SoCalBio Biomanufacturing Consortium to develop biomanufacturing technician education and training programs to support the maturation of the industry in Los Angeles/Orange Counties, CA; and a new program, Biotechnology and Compliance, focusing on biomanufacturing and partnered with local industry at Quincy College in Quincy, MA
Bioscience Presentation For Business Services StaffThomasSuggs
Presentation givento Jefferson County Workforce Center on needs of area bioscience companies and recommendations for how the WFC can better meet those needs.
Leading Molecules to Market - An overview on licensingBananaIP Counsels
Leading Molecules to Market - An overview on licensing
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Selling The Vision - Financial Communications for Life SciencesPaul McIvor
A brief introduction to key communications principles for life sciences companies looking to raise money from venture capitalists, grants or public offerings. Teaches you how to market your value proposition effectively.
Commercializing Science - February 2007Michael Gaiss
The document discusses commercializing scientific research from a venture capital perspective. It provides background on the author and their firm Highland Capital Partners. It then discusses the venture capital investing environment, the tech transfer environment at universities, and criteria for evaluating investment opportunities. The document concludes by presenting several case studies of successful companies spun out of universities that received venture capital funding, and emphasizes the importance of backing exceptional people.
The document summarizes a presentation by a venture capitalist on commercializing scientific research. It provides background on the VC, discusses the VC investing environment and tech transfer environment at universities. It then presents case studies of successful university spinouts, including Pervasis Therapeutics (MIT), Codon Devices (Harvard, Duke, Wisconsin), Magen Biosciences (Dana Farber), and Aveo Pharmaceuticals (Dana Farber, Harvard). It concludes with rules for VCs to successfully commercialize scientific research, emphasizing backing exceptional people and staying close to top research universities.
5 presentations on the challenges and options for science funding (health research) in Canada from a panel at the Canadian Science Policy Conference, 2013. Presenters: Christine Williams, Peter Goodhand, Jane Aubin, Phil Hieter and Jim Woodgett (chair).
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...Gary M. Myles, Ph.D.
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)
This document discusses strategies for addressing unmet medical needs through university intellectual property and licensing. It provides examples of the University of California, Berkeley's Socially Responsible Licensing Program, which includes contract clauses focused on access and affordability for neglected diseases and populations. The document outlines challenges in balancing commercial incentives with social welfare needs. It proposes combining contract terms, intellectual property strategies, and business models in different permutations to create incentives for developing products addressing unmet needs. Partnerships between universities, companies, and non-profits are presented as ways to accelerate innovation and de-risk product development for neglected areas.
The document discusses Mass CONNECT, a program that aims to leverage industry networks to advance translational research and bridge the "translation gap" between academic discoveries and early-stage commercial opportunities. The program provides mentoring, industry screening of technologies, and connections to proven industry advisors and networks to accelerate promising opportunities and increase the throughput of technologies out of academic offices. It describes the ideal profiles of technologies and investigators that would benefit from the program.
This document discusses the importance of collaborations between universities and industry, especially for natural product research. It notes that universities have become the primary source of biopharma innovation and discovery. However, natural product research presents challenges such as long timelines, complex sourcing and production, and uncertain patent and regulatory frameworks. The document emphasizes that university collaborations are critical for the biopharma industry to overcome these challenges. It also discusses the role of intellectual property in facilitating innovation through licensing between academia and industry.
Life Science Alternative Careers WorkshopMary Canady
This document summarizes a panel discussion on alternative careers for scientists. The panelists discussed their paths to careers in science writing, regulatory affairs, business development, and science policy. For science writing, the panelist recommended building a portfolio by volunteering to write and establishing goals. For regulatory affairs, the panelist discussed their transition from discovery research and strategies for gaining entry-level experience. Other panelists provided overviews of their careers in business development and policy fellowships. The discussion offered advice on networking, gaining relevant experience, and specializing to explore alternative career options outside of research.
The document discusses career opportunities in intellectual property for biomedical engineers, including working in patent law. It outlines that industry careers in areas like medical devices, diagnostics, and therapeutics involve intellectual property. For those interested in intellectual property specifically, skills in literature searching, patent searching, technical writing and understanding the medical industry are important. The document provides an example of analyzing disclosed inventions for commercialization potential as part of a job at an Office of Technology Management.
The document discusses the role of the UAB Research Foundation in technology transfer and commercializing intellectual property created at UAB. It notes that the RF handles around 1,000 agreements annually and owns the intellectual property from UAB's over $420 million in annual research expenditures. The RF aims to license patents and support Alabama's entrepreneurial ecosystem through collaborations within UAB and the local community that can help discoveries become commercial products and services.
What to know if it is your first rodeo in patent monetization.pptxturo6
What is patent monetization and how does it differ from a typical licensing deal?
The process of due diligence for patent monetization - how do you choose patents which would be great candidates for monetization?
What are some of the intangibles at institutions that prevent patent monetization?
How do you convince your institution about patent monetization?
The business model for patent monetization? Who pays for it? What's in it for me? What do net revenues vs gross revenue really mean in the context of monetization?
Legal considerations for patent monetization. What are some of the risks?
How long does it take? How do the recent policy changes and case law impact patent monetization?
Is patent monetization ethical?
These and many more topics will be covered in great detail with an opportunity to ask questions to the panelists who are world-leading experts in business, legal, and policy matters.
PLx Pharma is developing next generation NSAIDs to improve gastrointestinal (GI) safety. Jason Moore, Vice President of PLx Pharma, gave a presentation about positioning oneself for a leadership career in biotech and about the challenges faced by PLx Pharma, including developing drugs with improved GI safety profiles to address the large market for osteoarthritis pain relief while managing various risks in the drug development process such as technical, regulatory, financial and commercial risks.
The document discusses a manufacturing platform for producing therapeutics in tobacco plants. It summarizes meetings with experts on commercializing biotech platforms and understanding customers. Experts advised validating the platform by producing hard-to-make proteins, focusing on technical/manufacturing customers, and understanding regulatory issues. Customers cited interest in cost-effective production and combination vaccines. Next steps include further challenging the value proposition and better understanding commercialization and decision-making processes through additional expert meetings.
The document discusses best practices for technology transfer offices (TTOs) based on a conference presentation. It covers why technology transfer is important, key laws enabling tech transfer in the US, examples of university tech transfer success, and lessons learned regarding evaluating intellectual property, patenting, licensing, and starting new companies.
Presented by Dr. Tom Corr, CEO – Waterloo Research and Technology Park Accelerator Centre & Associate Vice President, Commercialization – University of Waterloo
Part of the Ontario Post Doctoral Fellowship Networking Event, October 6, 2008
TOPICS
Research Funding
Who Owns the Intellectual Property?
Commercialization Options
Dealing with VCs
Outcomes of Commercialization Efforts
Innovative and New Programs in Biotechnology and Biomanufacturing bio-link
This year’s panel features programs noteworthy in their approach to biotechnology/biomanufacturing education and training and the workforce. Panelists include leaders of the Lone Star Biotechnology Institute at Lone Star College working with the local biomedical and biofuels industry in Houston, TX; the Biomass Production Training Certificate at Mira Costa College part of the EDGE (Educating and Developing Workers for the Green Economy) initiative for San Diego County, CA; the SoCalBio Biomanufacturing Consortium to develop biomanufacturing technician education and training programs to support the maturation of the industry in Los Angeles/Orange Counties, CA; and a new program, Biotechnology and Compliance, focusing on biomanufacturing and partnered with local industry at Quincy College in Quincy, MA
Bioscience Presentation For Business Services StaffThomasSuggs
Presentation givento Jefferson County Workforce Center on needs of area bioscience companies and recommendations for how the WFC can better meet those needs.
Leading Molecules to Market - An overview on licensingBananaIP Counsels
Leading Molecules to Market - An overview on licensing
Contact Us for Intellectual Property Services
BananaIP Counsels
Regd Office
No.40,3rd Main Road,JC Industrial Estate,
Kanakapura Road,Bangalore – 560 062.
Email: contact@bananaip.com
Telephone: +91-80-26860414 /24/34
Selling The Vision - Financial Communications for Life SciencesPaul McIvor
A brief introduction to key communications principles for life sciences companies looking to raise money from venture capitalists, grants or public offerings. Teaches you how to market your value proposition effectively.
Commercializing Science - February 2007Michael Gaiss
The document discusses commercializing scientific research from a venture capital perspective. It provides background on the author and their firm Highland Capital Partners. It then discusses the venture capital investing environment, the tech transfer environment at universities, and criteria for evaluating investment opportunities. The document concludes by presenting several case studies of successful companies spun out of universities that received venture capital funding, and emphasizes the importance of backing exceptional people.
The document summarizes a presentation by a venture capitalist on commercializing scientific research. It provides background on the VC, discusses the VC investing environment and tech transfer environment at universities. It then presents case studies of successful university spinouts, including Pervasis Therapeutics (MIT), Codon Devices (Harvard, Duke, Wisconsin), Magen Biosciences (Dana Farber), and Aveo Pharmaceuticals (Dana Farber, Harvard). It concludes with rules for VCs to successfully commercialize scientific research, emphasizing backing exceptional people and staying close to top research universities.
5 presentations on the challenges and options for science funding (health research) in Canada from a panel at the Canadian Science Policy Conference, 2013. Presenters: Christine Williams, Peter Goodhand, Jane Aubin, Phil Hieter and Jim Woodgett (chair).
Similar to Career Options Life Scientist 04Jun10 (20)
This presentation discusses the patent application disclosure requirements under 35 U.S.C. Section 112 and relates, in particular, to the Supreme Court and Federal Circuit case law relevant to patent specifications and claims protecting inventions in the life sciences, biotechnology, and pharmaceutical industries
Commil v. Cisco: Brief of Biotechnology Industry Organization as Amicus Curi...Gary M. Myles, Ph.D.
Amicus Brief submitted by BIO (Biotechnology Industry Organization) to Supreme Court of the United States in Commil USA, LLC v. Cisco Systems (No. 13-896)
Biotechnology Patents: Utility and eligibility requirements under 35 USC 101. This presentation follows the historical development of the utility requirement from the early 19th century case Lowell v. Lewis (MA 1817), the origin of the specific, substantial, and credible standard for a patent disclosure from Brenner v. Manson (SCOTUS 1966), and the modern application of the Brenner standard for biotechnology patents in In re Fisher (Fed. Cir. 2005). Biotechnology eligibility requirements are discussed from the early Supreme Court case Funk Brothers v. Kalo, the seminal biotechnology Supreme Court case Diamond v. Chakrabarty (SCOTUS 1980) where the court holds that statutory subject matter includes "anything under the sun that is made by man," through the recent Supreme Court decision in Myriad v. ACLU (SCOTUS 2013) where the court held that diagnostic method claims and nucleic acid claims that read on products of nature are patent inelibible. Practice tips are provided to ensure that patent claims avoid the exceptions of 35 USC 101 and withstand scrutiny during litigation and business transactions, such as licensing.
The document discusses the disclosure requirements for biotechnology patents under 35 USC § 112. It covers topics like enablement, written description, and the statutory disclosure requirements. It summarizes several relevant court cases, including In re Wright, UC v. Eli Lilly, Enzo v. Gen-Probe, Chiron v. Genentech, and U. of Rochester v. Searle. The cases discuss how broad claims require broad disclosure, and that the specification must demonstrate possession of the full scope of the claims, including after-arising technologies. Undue experimentation and claims of undue breadth can result in lack of enablement.
This document provides an overview of different corporate structures for startups, including sole proprietorships, general partnerships, limited partnerships, limited liability partnerships, limited liability companies, and corporations (S-Corps and C-Corps). It discusses the key aspects of each structure such as liability, taxation, formation process, and pros and cons. The document recommends that for startups, the primary choices for corporate structure are limited liability companies, S-corporations, and C-corporations, and that the choice depends on factors like financing plans and investment levels. It also discusses considerations around incorporating in the state of the principal office or in Delaware.
The Federal Circuit's rule allowing a good-faith belief of patent invalidity to serve as a defense to induced infringement is inconsistent with the text of Section 271(b). Section 271(b) defines inducement based on direct infringement, not invalidity defenses. The Federal Circuit's rule conflates the separate defenses of invalidity and non-infringement and allows an inducer to avoid liability even if the invalidity defense lacks merit, bypassing the presumption of validity and clear and convincing evidence standard. The rule could encourage suits against end users and improper risk-shifting by inducers.
Merchant & Gould Whitepaper: Association of Molecular Pathology v. Myriad Ge...Gary M. Myles, Ph.D.
This Merchant & Gould whitepaper summarizes the holding of the recent Supreme Court Association of Molecular Pathology v. Myriad Genetics decision, outlines its impact, and provides practice tips to those endeavoring to protect nucleic acids, genes, cDNAs, and other biological molecules, including proteins and antibodies as well as diagnostic methods that relate to laws and products of nature.
This presentation addresses the why, what, and how to protect inventions from the vantage point of the early-stage, pre-financing, start-up company that is interested in patenting its inventions and developing an intellectual property portfolio that maximizes the company's valuation and sets it up for success during the intellectual property due diligence that accompanies financing rounds, corporate partnerships, commercialization, and merger and acquisition.
The document summarizes strategies that biotech companies can take to navigate challenges in obtaining financing. It recommends establishing strong policies and procedures, understanding complex agreements, and working with experts to avoid common pitfalls. Being prepared through measures like "audit-lite" reviews can help companies attract investors and limit risks.
This document summarizes recent developments in US patent law as it relates to patenting human DNA, embryos, and organs. It discusses Supreme Court cases that established that isolated DNA sequences and genetically modified organisms can be patented, but products of nature cannot. It describes the ongoing Myriad Genetics case regarding patents on human genes and recent legislation restricting patents on claims directed to human organisms. It concludes with an overview of developments in patenting stem cells and induced pluripotent stem cells.
America Invents Act: Recent Changes to US Patent Law and PracticeGary M. Myles, Ph.D.
The document summarizes changes brought by the America Invents Act to U.S. patent law and practice. Some key changes include transitioning from a first-to-invent system to a first-inventor-to-file system, expanding the definition of prior art, creating new post-grant review proceedings like post-grant review and inter partes review, expanding prior user rights, and changing treatment of errors in inventorship. The changes aim to harmonize the U.S. system with other countries and improve patent quality and challenge procedures.
This document provides an overview of biotechnology and recent patent law cases affecting patent eligibility of biotechnology inventions. It begins with primers on biotechnology topics like DNA, proteins, and therapeutic products. It then discusses why strong patent protection is essential for biotechnology given the lengthy and expensive research and development process. The document reviews various biotechnology patent claims and recent Supreme Court cases that have impacted patent eligibility of diagnostic methods, natural correlations, and processes applying natural relationships. It concludes with a discussion of personalized medicine and precision diagnostics representing future areas for biotechnology.
This document summarizes the agenda for a two-day symposium celebrating the 30th anniversary of the landmark Supreme Court decision in Diamond v. Chakrabarty. The symposium includes presentations and panels on September 21st and 22nd discussing the implications of the decision. The decision found that genetically modified life forms can be patented and helped launch the modern biotechnology industry. Speakers include the original plaintiff in the case, Dr. Ananda Chakrabarty, as well as legal and business experts discussing the impact on innovation, university research, and patent law.
This document summarizes the key statutory requirements for patentability in the United States, including novelty, non-obviousness, and disclosure requirements. It discusses how prior art references can anticipate claimed inventions either expressly or inherently, and how multiple references may render a claimed invention obvious. The level of ordinary skill in the art and secondary considerations must be considered for obviousness. Later Supreme Court cases further refined how obviousness is determined.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
1. Career Options for
the Professional Life Scientist
Fred Hutchinson
Cancer Research Center
June 4, 2010
Gary M. Myles, J.D., Ph.D.
Shareholder
Schwabe, Williamson & Wyatt
Seattle, Washington
2. Summary
l Do we produce too many science PhDs?
– Disconnect between science education and
career opportunities
– Central role of PhD in many science careers
l A brief history of biotechnology
– Merging of academic and commercial pursuits
l Biotechnology opportunities for the
professional scientist
3. Are There Too Many PhDs?
l The dirty secret of higher education is that without underpaid graduate
students to help in laboratories and with teaching, universities couldn’t
conduct research or even instruct their growing undergraduate populations.
That’s one of the main reasons we still encourage people to enroll in
doctoral programs. It is simply cheaper to provide graduate students with
modest stipends and adjuncts with as little as $5,000 a course — with no
benefits — than it is to hire full-time professors.
l In other words, young people enroll in graduate programs, work hard for
subsistence pay and assume huge debt burdens, all because of the illusory
promise of faculty appointments. But their economical presence, coupled
with the intransigence of tenure, ensures that there will always be too many
candidates for too few openings.
Mark C. Taylor, “End the University as We Know It” New York Times, 26Apr09
4. Many of the Newly Minted PhDs are in
Biological Sciences and Engineering
7. Traditional Career Paths for
the PhD Scientist
Academic Career Industry Career
BS
BS
MS
MS
PhD
PhD
Post Doc
Post Doc
Scientist
Assistant Professor
Senior Scientist
Associate Professor
Assistant Director
Professor
Director
Department Head
Senior Director
Dean
Vice President
Chief Scientific Officer
8. Disconnect between University
Education and Science Career Options
l Historically, academic institutions have not
promoted non-academic career paths for
professional scientists
– Little cross-disciplinary teaching at the
undergraduate and graduate levels
l Between technologies
l Between professions (science/business/law)
– Little counseling about or practical exposure to
non-academic career options for scientists
– Tendency to stigmatize students who express an
interest in non-academic science careers
9. Disconnect between University
Education and Science Career Options
l Students are entering universities to pursue
academic science careers often overlook,
discount, or are unaware of the low
probability that they will stay in academic
science
l Students are leaving universities without a
vision for non-academic science careers
10. 1980 – A Seminal Year for
Biotechnology
l 370 US licensees (non-exclusive)
l Est. $200MM in licensing revenue
11. 1980 – A Seminal Year for
Biotechnology
1980
l Bayh-Dole Act
(University and Small Business
Patent Procedures Act)
l Birch Bayh and Bob Dole
l Basis for university technology
transfer
l Intellectual property arising
from federal government-
funded research controlled by
US universities, small
businesses, and non-profits
12. 1980 – A Seminal Year for
Biotechnology
1980
l Diamond v. Chakrabarty
(Supreme Court)
l Patentability of living,
genetically engineered
microorganisms under
35 U.S.C. § 101
l “Anything under the sun
that is made by man”
13. Shift in Focus of Research Efforts
toward Commercialization
l The Problem of Publish or Perish
– Tragedy of Freedom in the Commons
l When a resource is open to all it becomes available to no
one Garrett Hardin, “The Tragedy of the Commons” Science 162:1243-1258 (1968)
l “This concept is readily adapted to the quandary that the
great discoveries in biomedical research in the 1960s and
1970s did not benefit the public” Howard Schachman, “From ‘Publish or
Perish’ to ‘Patent and Prosper’ ”, J. Biol. Chem. 281(11):6889-6903 (2006)
Taxpayer $ NIH/NSF Publication
14. Shift in Focus of Research Efforts
toward Commercialization
l Howard Schachman,
“From ‘Publish to
Perish’ to ‘Patent and
‘Prosper’ ” JBC (2006)
15. Shift in Focus of Research Efforts
toward Commercialization
l Patent and Prosper
– The incentive of companies to commercialize
derives from the exclusive rights to manufacture
that are afforded by the patent system
Taxpayer $ NIH/NSF Publication Patent
Technology Transfer
Commercialization
19. Top 3 US Market Capitalization (10/07)
l Exxon Mobil Corp., $511B
l General Electric, $414B
TOTAL BIOTECHNOLOGY WORLDWIDE $410B
l Microsoft Corp., $328B
20.
21. The Biotechnology Industry
Operates at a Loss
l In 2008, the global biotech industry lost $1.4
billion (down from 2007's loss of $3 billion)
l The U.S. segment of the biotech industry
made a profit in of $0.4 billion in 2008
Ernst & Young, “Beyond Borders: Global Biotechnology Report 2009”
22. The Major Players in Biotechnology
Sources of Financing
Sources of Technology and
(Public (SBIR/STTR),
Intellectual Property
Private (Angels and VC), and
(Universities and Non-profits)
Big Pharma/Biotech)
The Biotech Companies
Incubators
Law Firms
(Service Providers)
23. Biotech Companies Require
Cross-disciplinary Expertise
Technology
- Protein/Antibody
- DNA/RNA
- Small molecule
- Diagnostics MBA/PhD
JD/PhD
Business
- Deals
• In/out licenses
Law • Corporate Partners
JD/MBA
- Corporate • Mergers & Acquisitions
• Licenses and other agreements - Venture Financing
- Intellectual Property
• Patents, copyrights, trademarks, and
trade secrets
24. The PhD is Central to Many
Science Career Paths
Academic Science
Industrial Science
Science Policy/Think Tank
Technology Transfer
Regulatory
BS MS PhD MD
• Clinical Trials/FDA Approval
Business Development
MBA
• Dealmaking
Venture Financing/Investment Banking
MBA
• Due Diligence
JD Law
• Patent Prosecution
(See, UCSF Office of Career and Professional Development) • Litigation
• Licensing
25. A Few Thoughts on Strategy
l Opportunity Cost of Education
– For every additional step in your education, keep
in mind the lost opportunity to earn
– Education is expensive
l Law of Diminishing Returns
– It takes time to extract 100% value
(learning/growth) out of every position/opportunity
– Shoot for 80% value
– Consider 3 year blocks
– If not moving up, move on
26. Make Yourself Uniquely Qualified
l Take a Cross-disciplinary Approach
– Professionally
l Work at the interface between professions
– Science + Law
– Science + Business
– Technology
l Contemplate the future of technology
l Develop expertise in a number of technologies
– Science + Engineering
28. Identify Thought Leaders
l Founded in 2000 by Lee
Hood, Alan Aderem, and
Ruedi Aebersold
l Mission of transforming
biological and medical
research by creating and
using systems approaches
to unravel the workings of
complex biological systems
l P4 Medicine
– Personalized
– Preventative
– Predictive
– Participatory
29. Networking
l Networking is the on-going process of
relationship building
– Life-long, persistent, goal and result
oriented
– Based on the premise that
l Careers don’t develop in isolation
l No one person can know everything
l People want to do business with people
they like and trust
30. Networking
l Starts at the university level
– Attend seminars and networking events outside
your department
l Business
l Law
l Medicine
l Technology
– Other Cultures
l India and China next dominant economic
powers?
31. Networking
l Continue throughout your career
– Trade and professional meetings
– Entrepreneur networks
– Teaching and mentoring
32. Some Parting Words of Wisdom
l When one door closes, another opens. But we often
look so long and so regretfully upon the closed door
that we do not see the one which has opened for us.
Helen Keller
l If opportunity doesn’t knock, build a door.
Milton Berle
33. Thank you!
Gary M. Myles, J.D., Ph.D.
Schwabe, Willamson & Wyatt
gmyles@schwabe.com
(206) 407-1513
41. Early Efforts to Commercialize
Biotechnology Products
1976
l Founding of Genentech
(Genetic Engineering
Technology, Inc.)
l Robert Swanson and
Herbert Boyer
l Synthetic human insulin
42. Early Efforts to Commercialize
Biotechnology Products
1978
l Biogen
l Phil Sharp and Walter
Gilbert
l Interferon
43. Early Efforts to Commercialize
Biotechnology Products
1980
l AMGen (Applied
Molecular Genetics)
l George Rathman,
Franklin “Pitch”
Johnson, Joseph
Rubinfeld, Winston
Salser, Lee Hood, and
Bill Bowes